What the FDA labels say about taking them together
Fingolimod and haloperidol
Fingolimod's FDA label of July 22, 2026 names haloperidol in its drug interactions section; the haloperidol labels PlainMeds reads (2) do not name fingolimod. The fingolimod label: “Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes should be monitored overnight with …”
Check it at the source: the fingolimod FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation); the haloperidol FDA label on DailyMed (effective April 23, 2026, PD-Rx Pharmaceuticals, Inc.).
What does the fingolimod label say about haloperidol?
Fingolimod label, drug interactionsSince initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility [see Dosage and Administration (2.4), Warnings and Precautions (5.1)].
Fingolimod label, warnings and precautionsSince initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients with a prolonged QTc interval (> 450 msec adult and pediatric males, > 470 msec adult females, or > 460 msec pediatric females) before dosing or during 6-hour observation, or at additional risk for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital long-QT syndrome), or on concurrent therapy with QT prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility.
Source: FDA drug label (Tascenso Odt, NDA214962), Cycle Pharmaceuticals Ltd, effective January 20, 2026 (SPL set bf8e7f89-ea09-43c7-a7eb-e44724350721), via openFDA
Source: FDA drug label (Gilenya), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set cc9e1c8c-0e2b-44e2-878b-27057f786be9), via openFDA; the full label on DailyMed
What does the haloperidol label say about fingolimod?
Haloperidol's label (effective April 23, 2026) and its 1 other brand-application label do not name fingolimod in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Haloperidol), PD-Rx Pharmaceuticals, Inc., effective April 23, 2026 (SPL set 533b0b4c-cbd6-4ec0-a333-8b04b5b43a1d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fingolimod | Haloperidol | |
|---|---|---|
| Labeled for | Multiple sclerosis | Schizophrenia |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.58 per capsule 0.5 mg capsule | $15.60 per mL 100 mg/mL vial |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once